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The purpose of present study was aimed at developing self emulsifying drug delivery system in liquid 
and then in pellet form that would result in improved solubility, dissolution and permeability of the 
poorly water soluble drug carvedilol. Pellets were prepared using extrusion-spheronization technique 
incorporating liquid SEDDS (carvedilol, capmul MCM EP, cremophore EL, tween 20, propylene 
glycol), adsorbents ( and crospovidone), microcrystalline cellulose and binder (povidone K-30). Ternary 
phase diagram was constructed to identify different oil-surfactant-cosurfactant mixtures according to 
the proportion of each point in it. The optimal CAR-SEDDS pellets showed a quicker redispersion 
with a droplet size of the reconstituted microemulsion being 160.47 nm, which was almost unchanged 
after solidification. SEM analysis confirmed good spherical appearance of solid pellets; DSC and XRD 
analysis confirmed that there was no crystalline carvedilol in the pellets. Pellets were then capable of 
transferring lipophilic compounds into the aqueous phase and significantly enhancing its release with 
respect to pure drug.
Uniterms: Drugs/self emulsifying/delivery system. Pellets/self emulsifying/preparation. Pellets/self 
emulsifying/delivery system. Carvedilol/pharmacokinetics.
O propósito do presente estudo foi desenvolver um sistema líquido de liberação de fármacos auto 
emulsificante e, então, na forma de pélete, que poderia resultar em aprimoramento da solubilidade, 
da dissolução e permeabilidade do fármaco carvedilol, pouco solúvel em água. Os péletes foram 
preparados utilizando-se a técnica de extrusão-esferonização, incorporando líquido SEDDS (carvedilol, 
capmul MCM EP, Cremofor EL, Tween 20, propileno glicol), adsorventes (e crospovidona), celulose 
microcristallina e ligante (povidona K-30). O diagrama de fase ternário foi construído para identificar as 
misturas diferentes de óleo-tensoativo-co-tensoativo, de acordo com a proporção em cada ponto delas. 
Os péletes CAR-SEDDS mostraram redispersão mais rápida, com tamanho de gota da microemulsão 
reconstituída de 160,47 nm, que se mostrou quase inalterada após a solidificação. A análise por SEM 
confirmou a aparência esférica dos péletes sólidos. Análise por DSC e XRD confirmou que não havia 
carvedilol cristalino nos péletes. Estes foram, então capazes de transferir os compostos lipofílicos para 
a fase aquosa, aumentando, significativamente, sua liberação em relação ao fármaco puro. 
Unitermos: Fármacos/sistema líquido de liberação auto emulsificante. Péletes/auto emulsificante/
preparação. Péletes/auto emulsificante/sistema líquido de liberação. Carvedilol/farmacocinética.
INTRODUCTION
In recent years, an increasing number of new 
chemical entities and many already existing drugs show 
low aqueous solubility, which are prone to poor oral 
absorption, high intra-inter-subject variability and lack 
of dose availability. Thus, to increase solubility of drugs 
which are mainly BCS II type, various solubilization 
techniques or formulation strategies have been developed 
like the use of cyclodextrins, nanoparticles, solid 
dispersions, permeation enhancers, liposomes, etc. (Wang 
et al., 2010).
Self-emulsifying drug delivery system (SEDDS) is 
among the methods used to improve the oral bioavailability 
of poorly soluble drugs by presenting and maintaining the 
drug in a dissolved state, in small droplets of oil, all over its 
transit through the gastrointestinal tract (GIT). SEDDS are 
composed of a mixture of oil, surfactant and cosurfactant 
V. Bhandari, A. Avachat664
that are capable of forming oil-in-water emulsions upon 
gentle agitation provided by the GIT motion (Abdalla, 
Klein, Mader, 2008).
However, SEDDS are present in the liquid state, 
which can be packed in hard or soft gelatin capsule directly 
but suffer from the drawbacks related to stability and 
compatibility. Incorporation of liquid SEDDS into solid 
dosage form is therefore compatible and desirable where 
spray drying, self emulsifying granules, tablet or pellets 
can be a preferred and viable option (Iosio et al., 2008).
Pellets have many advantages, over conventional 
solid dosage forms viz; flexibility in designing and 
developing the dosage form and improving the safety 
and efficacy. Because the pellets disperse freely in the 
gastrointestinal tract, drug absorption is maximized with 
a subsequent reduction in peak plasma fluctuations and 
hence minimizing potential side effects without lowering 
drug bioavailability. The pellets also reduce variations in 
gastric emptying rates and overall transit time and therefore 
a reduction of intra and inter-subject variability of plasma 
profiles is achieved. In addition, pellets reduce the problem 
of high local concentration of drugs and thus avoiding 
irritation that may be caused by certain active constituents. 
The most widely used techniques for pellet production in 
the pharmaceutical industry are extrusion/spheronization 
(ES), solution/suspension layering, and powder layering. 
The process of ES has become the method of choice in the 
preparation of pellet-based dosage forms since it offers 
many advantages over the other methods, including the 
spherical shape with a narrow size distribution, good flow 
properties, low friability, uniform packing characteristics 
and reproducible scalability (Abdalla, Mader, 2007).
Carvedilol is a non-selective beta-blocker indicated 
in the treatment of mild to moderate congestive heart 
failure (CHF). It blocks beta-1 and beta-2 adrenergic 
receptors as well as the alpha-1 adrenergic receptors 
and is classified according to the Biopharmaceutical 
Classification System as a drug with low solubility and 
is presented as an immediate-release dosage form in the 
WHO essential drug list. Carvedilol is available in the 
market in 3.125, 6.25, 12.5, and 25mg tablets. Its serum 
concentration is not only affected by its low solubility 
but also by P-glycoprotein (P-gp) activity and first pass 
metabolism (http://www.drugbank.ca/drugs/DB01136).
In this study, we developed a novel CAR-loaded 
SEDDS pellets using extrusion-spheronization technique. 
An efficient CAR-SEDDS formulation was evaluated 
by solubility study, self-emulsifying grading test, 
phase diagrams, and redispersibility study. Finally, the 
optimum pellets were characterized by scanning electron 
microscopy (SEM), differential scanning calorimetry 
(DSC), X-ray diffraction (XRD), and reconstitution test 
(Hua et al., 2012).
MATERIAL AND METHODS
Material
Carved i lo l  was  k ind ly  g i f t ed  by  Medley 
Pharmaceuticals Ltd. Capmul MCM EP, capmul PG12, 
captex 500, captex 300 were gifted by Abitec Corp., 
USA. Capryol 90, labrafil M 2125 CS, labrafil M 2130 
CS, labrafac CC, labrasol, lauroglycol FCC, transcutol P 
were supplied by Gattefosse, France. Oleic acid, tween 
80, tween 20, span 20, span 80, propylene glycol, PEG 
400, PEG 200 was purchased from Loba Chemie Pvt. 
Ltd., Mumbai. Cremophore EL, cremophore RH 40 were 
obtained from Signet Chemicals, Mumbai. Polaxamer 
407, solutol HS 15 was supplied by BASF. MCC PH 
101 was obtained from RanQ Pharmaceuticals Nashik. 
Crospovidone, povidone K-30 and were obtained from 
and used in R & D Medley Pharmaceuticals Ltd., Mumbai.
Solubility of carvedilol
The solubility of carvedilol in various oils, surfactants 
and co surfactants was determined by using the shake flask 
method. An excess amount (50 mg) of carvedilol was added 
to each vial containing 1ml of the selected vehicle i.e. oil, 
surfactant or cosurfactant. Oils used were capmul MCM 
C8, capryol 90, labrafil M 2125, labrafil M 2130, captex 
500, captex 300, oleic acid, capmul PG 12, capmul MCM 
EP. Surfactants was selected from labrafac, cremophore EL, 
cremophore RH 40, labrasol, tween 20, tween 80, solutol 
HS 15, polaxamer 407; while propylene glycol, PEG 400, 
transcutol P, span 20, PEG 200, lauroglycol FCC, span 80 
were used as cosurfactants. After sealing of each vial proper 
mixing of carvedilol with the vehicles was done in order to 
facilitate solubilization. Mixtures were shaken for 48 h in a 
mechanical shaker maintained at room temperature. After 
48h each vial was centrifuged at 5,000 rpm for 10min. 
Undissolved carvedilol was removed by filtering through 
0.44 µ Whatman filter paper. Aliquots of filtrate were diluted 
with methanol, and the concentration of dissolved carvedilol 
was quantified by U.V. Spectrophotometer at 285 nm (Hua 
et al., 2012).
Selection of surfactant and cosurfactant
The self - emulsification ability of surfactants was 
assessed to select the best surfactant from a large pool of 
surfactants. Selected oil and different surfactants were 
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mixed in 1:3 (v/v) and vortexed to form a homogenous 
mixture (Borhade, Nair, Hedge, 2008). The ratio of oil to 
surfactant was decided on the basis of the requirements 
stated by Pouton for spontaneously emulsifying systems 
and represents a Type III system. Oil-surfactant mixture, 
1 mL dispersed in 100 mL of double distilled water in a 
glass beaker was mixed with gentle stirring. Visual test 
was used to assess self-emulsification of surfactants in 
terms of dispersibility, ease of emulsification and final 
appearance using a grading system as mentioned below. 
Various cosurfactants were screened by mixing them with 
the selected surfactants in 1:2 v/v ratio. An oily phase was 
added to each of this (S+Co-S) mixture in 1:3 (v/v) and 
vortexed gently to form a homogenous mixture. They 
were evaluated using a visual test as explained below. 
The emulsions were allowed to stand for 2 h and their 
transmittance was measured at 638.2 nm by UV-1800 
double beam spectrophotometer (Shimadzu, Japan) using 
double distilled water as blank (Date, Nagarsenker, 2007).
Self emulsifying grading test
The selected oil, surfactants, and cosurfactants were 
homogenized at different ratios (4:4:2, 3:4:3, 2:4:4 etc. 
v/v/v) in eppendrof tubes by vortexing for 5 min. Then 1 
mL of the mixture that has a transparent appearance was 
added to 100 mL water with magnetic stirring (50 rpm) 
to determine the emulsion forming process and final 
appearance, which has been divided into four grades using 
a visual grading system.
Grade A: Rapid forming micro emulsion, which is 
clear or slightly bluish in appearance, self-emulsification 
time- less than 1 min.
Grade B: Rapid forming, slightly less clear emulsion, 
which has a bluish white appearance, self-emulsification 
time-less than 2 min.
Grade C: Bright white emulsion (similar to milk 
in appearance), self-emulsification time-less than 2 min.
Grade D: Dull, grayish white emulsion with a 
slightly oily appearance that is slow to emulsify, self-
emulsification time-more than 2 min.
Construction of ternary phase diagram
Ternary diagrams of surfactant, cosurfactant and 
oil were plotted using ProSim software; each of them, 
representing an apex of the triangle. Ternary mixtures with 
varying compositions of oil, surfactant, and cosurfactant 
were prepared. For any mixture, the total of surfactant, 
cosurfactant and oil concentrations always added to 
100%. The large numbers of such mixtures with varying 
surfactant, cosurfactant and oil concentrations were 
prepared in this investigation as mentioned in Table I and 
Table II. The percentage of surfactant, cosurfactant and oil 
used herein was decided based on the requirements stated 
by Pouton for the spontaneously emulsifying systems. 
Compositions were evaluated for SEDDS formation by 
diluting 100µl of each of the mixtures to 10ml double 
distilled water. The globule size of the resulting dispersion 
was determined by Nanophox (NX0088). Dispersions, 
having globule size 250nm or below were considered 
desirable. The area of SEDDS formation was identified in 
the ternary system based on the desired globule size (Date, 
Nagarsenker, 2007).
Formulation optimization of SEDDS
SEDDS were optimized for following parameters:
·	 Drug loading
·	 Amount of oily phase
·	 Droplet size
Different batches of SEDDS were prepared as shown 
in Table I and Table II. Oil, surfactant and cosurfactant 
were accurately measured and mixed using stirrer 
followed by vortex mixing until a solution (CAR-SEDDS) 
was obtained (Setthacheewakul et al., 2010).
Development of CAR-SEDDS pellets
Preparation of CAR-SEDDS pellets
SEDDS 20ml containing carvedilol 5% was 
adsorbed on (specific surface area 110 m2/g). This was 
TABLE I - Different batches of SEDDS (primary batches)
Ingredients (µL) X1 X2 X3 X4 Y1 Y2 Y3 Y4
Capmul MCM EP 100 200 300 400 100 200 300 400
Cremophore EL 600 533 467 400  --  --  --  --
Tween 20  --  --  --  -- 600 533 467 400
S/CoS ratio 2:1 2:1 2:1 2:1 2:1 2:1 2:1 2:1
Propylene glycol 300 267 233 200 300 267 233 200
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further passed through mesh size 30 (595 microns) 
and mixed with microcrystalline cellulose PH 101, 
crospovidone, povidone K-30 in planetary mixture for 
10min. Sufficient quantity of water was added to form a 
wet mass. This wet mass was then extruded through the 
extruder (Umang Pharmatech Pvt. Ltd. Mumbai, India) 
at 10 rpm which was then spheronised on spheroniser at 
500 rpm for 2-5 min. Pellets were dried in hot air oven 
at 60 °C for 40 min. Dried pellets were passed through 
mesh size 16 (1190 microns) to get uniform sized pellets. 
Pellets were filled into size 0 hard gelatin capsules 
(Iosio et al., 2011).
Characterization of CAR-SEDDS and CAR-SEDDS 
pellets
Scanning electron microscopy (SEM)
The outer macroscopic structure of the pellets was 
examined by scanning electron microscopy (JEOL JSM-
6360 A). Prior to microscopy, samples were coated with 
carbon by sputtering for 2 min by autofine coater (JEOL 
JFC-1600).The samples were scanned at a voltage of 10 
kV (Zhang et al., 2012).
Differential scanning calorimetry (DSC)
The physical state of carvedilol in solid SEDDS 
was characterized by the differential scanning calorimetry 
analysis by DSC-SIO6300, Japan. The sample (about 
2.5 mg) was placed on standard aluminum pans, and dry 
nitrogen was used as effluent gas. The sample was scanned 
at a scanning rate of 10°C/ min between 40-260 °C and 40 
ml/min nitrogen flow (Prabagar et al., 2009).
X-ray powder diffraction (XRPD)
To verify the physical state of carvedilol in solid 
SEDDS, X-ray powder scattering measurement were 
carried out with an X-ray diffractometer (Bruker AXS, 
DH Advanced, Germany) at room temperature using 
monochromatic CuKα-radiation (k = 1.5406 Å) at 30 mA 
and at 40 kV over a range of 2q angles from 0 ° to 40 ° 
with an angular increment of 0.02 °per s (Yi et al., 2008).
Reconstitution study
Solid SEDDS 100 mg prepared as described above 
were dispersed in 10 mL distilled water, by vortex mixing 
(30 s), and then incubated for 30 min at 25 °C (Borhade, 
Nair, Hedge, 2008). The particle size of reconstituted 
solid SEDDS emulsion was determined by Nanophox 
(NX0088) (Yi et al., 2008).
In vitro dissolution Test
The quantitative in vitro release test was performed 
in 500 mL of 0.1 N HCl using USP XXIV dissolution 
apparatus 1. The basket was rotated at 50 rpm. The liquid 
and solid SEDDS formulations (pellets in hard gelatin 
capsules) were analysed to dissolution studies. Results 
were compared with those of plain drug and marketed 
formulation. During the release studies, 5 mL sample of 
the medium was taken out and subjected to drug analysis 
using UV spectrophotometrically at 285 nm. The removed 
volume was replaced each time with 5ml of fresh medium. 
Similarly, dissolution studies were also done in pH 4.6 
acetate buffer and pH 6.8 phosphate buffer to study the 
effect of pH on carvedilol release.
Permeability studies
The methods employed were modified with respect 
to the experimental procedures described in the literature. 
To check the intraduodenal permeability, the duodenal 
part of the small intestine of the chick was isolated and 
taken for in vitro diffusion study. Then this tissue was 
thoroughly washed with Ringer’s solution to remove the 
mucous and lumen contents. The liquid SEDDS sample 
was diluted with 1 mL of distilled water while for the tablet 
and pellet sample a suspension was made in distilled water. 
The resultant sample (6.25 mg/mL) was injected into the 
lumen of the duodenum using a syringe, and two ends of 
intestine were tightly closed. Then the tissue was placed 
in a chamber of organ bath with continuous aeration. The 
receiver compartment was filled with 30 ml of phosphate-
buffer (pH 6.8). The absorbance was measured using a 
UV-VIS spectrophotometer at a wavelength of 285 nm. 
TABLE II - Different batches of SEDDS (final batches)
Ingredients (µL) F1 F2 F3 F4 F5 F6
Capmul MCM EP 350 400 450 350 400 450
Cremophore EL 433  400 367  --  --  --
Tween 20  --  --  -- 433 400 367
Propylene Glycol 217 200 183 217 200 183
Droplet Size (nm) 136.22±1.32 142.89±1.17 246.29±1.38 213.63±1.27 244.95±1.24 291.83±1.15
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The percent diffusion of the drug was calculated against 
time and plotted on a graph (Ghosh et al., 2006).
RESULTS AND DISCUSSION
Solubility of carvedilol
Among the various oils higher solubility of carvedilol 
was found in capmul MCM EP, so it was selected as the 
oil phase. Data suggested that drug has more solubility in 
MCT rather than LCT because medium chain triglycerides 
(MCT) possess higher ester content per gram than long 
chain triglycerides (LCT), so drug has higher solubility in 
MCT than LCT Among the various surfactants, solubility 
of carvedilol was found highest in labrasol, cremophore 
EL and tween 20 while among the cosurfactants higher 
solubility was found in transcutol P, propylene glycol, 
polyethylene glycol 200. According to self emulsification 
ability and % transmittance study cremophore EL and 
tween 20 were selected as sufactants and propylene glycol 
was selected as cosurfactant for further study. Solubility of 
carvedilol in various vehicles (oil, surfactant, cosurfactant) 
is shown in Figure 1.
Self-emulsifying grading test
It was seen that as the oil component increases in the 
formulation beyond a certain limit there was generation 
of non-clear dispersion. Among the X1-X4 and Y1-Y4 
the X3, X4, Y3, Y4 show grade B while X1, X2, Y1, Y2 
exhibited grade A type emulsion. Formulation F1-F6 
shows grade B type of emulsion.
Ternary phase diagrams
Ternary phase diagrams of oil (capmul MCM EP), 
Surfactants (cremophor EL, tween 20) and cosurfactant 
(Propylene glycol) were constructed (Figure 2).The largest 
microemulsion region was observed when cremophore EL 
was used as surfactant. The coloured region indicates better 
self-emulsification region. Self-emulsion formation area 
was increased with an increase in surfactant concentration.
Formulation optimization of SEDDS
Based on the ternary phase diagram, eight different 
preliminary batches of SEDDS were formulated using 
capmul MCM as oil, cremophore EL and tween 20 as a 
surfactant and propylene glycol as cosurfactant (Table 
I). For further characterization through particle size 
analysis formulation, which contained cremophore EL 
as a surfactant showed lower particle size than other 
formulations. Different batches F1-F6 (Table II) were 
prepared using capmul MCM EP, cremophore EL, tween 
20 and propylene glycol.
Though the batch containing 10% oil had the least 
particle size the required amount of carvedilol could not 
be solubilized into it. The same was the case with SEDDS 
containing 20 or 30% oil. Beyond 40% the globule size FIGURE 1 - Solubility of carvedilol in various vehicles (oil, surfactant, cosurfactant).
FIGURE 2 - Ternary phase diagram.
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was get increased which was not acceptable. So, according 
to % of oil content, drug loading and droplet size analysis 
formulation F2 and F5 were taken for further study.
Development of CAR-SEDDS pellets
Preparation of CAR-SEDDS pellets
Solid SEDDS were successfully prepared using 
colloidal silicon dioxide and microcrystalline cellulose PH 
101 as a solid carrier, crospovidone as a disintegrant and 
povidone K-30 is as a binder. Solid pellets were prepared 
using an extrusion-spheronization technique and then 
filled into 0 size gelatin capsule.
Characterization of CAR-SEDDS pellets
Scanning electron microscopy (SEM)
Pellet surfaces and cross-sections were studied using 
scanning electron microscope. As shown in Figure 3 SEM 
micrographs of carvedilol-SEDDS pellets reveal that the 
pellets had a spherical shape. Carvedilol-SEDDS appear 
to be entrapped in the matrices. The images show that the 
surface of the pellets is full of pinholes, which probably 
allow the ingress of the aqueous phase into the matrix, and 
allow diffusion of the entrapped carvedilol from SEDDS 
out of the surface and the core of the matrix. Due to this, 
the liquid carvedilol-SEDDS is released through the mini-
channels and then forms oil-in-water microemulsion thus 
making carvedilol ready for absorption as an oily droplet 
solution.
Differential scanning calorimetry (DSC)
The physical state of carvedilol in the solid SEDDS 
was investigated since it would have an important 
influence on the in vitro and in vivo release characteristics. 
DSC curves of pure carvedilol and the solid SEDDS of 
carvedilol are shown in Figure 4. Pure carvedilol showed 
a sharp endothermic peak at a temperature of 116 °C 
corresponding to its melting point. No obvious peak of 
the drug was found in the solid SEDDS of carvedilol, 
indicating that the drug must be present in the molecularly 
dissolved state in solid SEDDS.
X-ray powder diffraction (XRPD)
From X-ray powder diffractograms shown in 
Figure 5, the internal physical state of carvedilol in the 
solid SEDDS was further verified. No obvious peaks 
representing crystals of carvedilol were seen for the 
solid SEDDS, indicating that the drug is present in the 
molecularly dissolved state in solid SEDDS (Dixit, 
Nagarsenker, 2008).
Reconstitution properties of CAR-SEDDS pellets
The average droplet size of emulsion from both 
liquid and solid SEDDS was less than 250 nm. The 
droplet size of the emulsion from the solid SEDDS was 
no significantly different from the droplet size of the liquid 
SEDDS. From these results, incorporating the liquid 
SEDDS in colloidal silicon dioxide and MCC PH 101 by 
extrusion and spheronization did not have a remarkable 
effect on droplet size. The solid SEDDS preserved the 
self-emulsification performance of the liquid SEDDS. 
Droplet size of liquid SEDDS is 142.89 nm and that of 
solid SEDDS is 160.47 nm.
The mean droplet size of the diluted SEDDS 
preconcentrates was low, and all were found to be in the 
FIGURE 3 - SEM images of pellets and pellet surface.
FIGURE 4 - DSC of carvedilol and CAR SEDDS pellets.
FIGURE 5 - XRD of carvedilol and CAR SEDDS pellets.
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nanometric range (20-250nm). Droplets size results of 
SEDDS formulation are reported in Table III. In all eight 
formulations, which were tested, the droplet size increased 
upon decreasing ammount of S+Co-Smix. SEDDS shows 
good uniformity in the droplet size distribution even after 
diluted with water.
In vitro dissolution Test
As shown in Figure 6, the release performance of 
CAR from solid and liquid SEDDS was significantly 
improved compared to conventional tablets and plain drug. 
From the in vitro dissolution studies, it was observed that, 
plain drug showed very less release (46%) after 60 min, 6.25 
mg immediate release tablet showed only 68% release after 
60 min, whereas, liquid SEDDS showed a rapid release of 
75% (F2) and 65% (F5) in 0.1 N HCl in just 10 min and 
86%(F2) and 80%(F5) in 20 min. Solid SEDDS showed a 
release of 90% (F2) and 80% (F5) within 30 min only.
Figure 7 illustrates that, % drug release from CAR 
SEDDS pellets was 100% and surprisingly same at 
different pH conditions viz; 0.1 N HCl, pH 4.6 and pH 6.8 
buffer while plain drug does not show it. This indicates that 
SEDDS has rendered the release of carvedilol independent 
of the pH which is not so with the plain drug nor with the 
marketed product.
Carvedilol as such is reported to have pH dependant 
solubility, maximum solubility being in the acidic pH. 
One of the objectives of the present study was also to 
nullify the effect of pH on the release of carvedilol so as to 
achieve uniform drug release through GIT. So, the release 
of carvedilol, the prepared CAR-SEDDS and the marketed 
product was seen in different pH conditions, which mimic 
the in-vivo conditions.
Permeability studies
In vitro intestinal permeability data are shown in 
Figure 8. The drug diffused at a faster rate from the SEDDS 
than from the tablet dosage form. The total percentage 
diffusion was much higher for the SEDDS than for the 
tablet dosage form. After 1 hour of diffusion, 97.8% of the 
drug was diffused from the liquid SEDDS, as compared 
to 91% from the CAR-SEDDS pellets and 32% from 
marketed tablet.
TABLE III - Droplet size of SEDDS
Batch X1 X2 X3 X4 Y1 Y2 Y3 Y4 
Droplet 
size(nm) 23.41±0.64 33.41±0.55 130.89±0.68 144.84±1.27 37.62±0.58 69.25±0.67 196.33±0.64 249.58±1.38
FIGURE 6 - In vitro Dissolution release study of marketed drug, 
plain drug and CAR-SEDDS pellet formulations F2 & F5 in 
0.1 N HCl, where, L F2-SEDDS F2,L F5-SEDDS F5,S F2-solid 
SEDDS F2,S F5-solid SEDDS F5, MR-marketed formulation, 
Plain-plain drug tablet.
FIGURE 7 - Effect of pH on carvedilol release.
FIGURE 8 - In vitro intestinal permeability of liquid SEDDS, 
pellets and marketed formulation.
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CONCLUSION
Carvedilol has only 25-35% absolute bioavailability 
due to high first pass metabolism and insolubility in water. 
The present research work was directed towards the 
development of SEDDS which were incorporated into 
pellets, which would increase solubility and permeability 
of carvedilol.
Type of oil, surfactant and cosurfactant concentration 
play a vital role in SEDDS formation. Based on the 
solubility studies capmul MCM EP was selected as oil 
phase, cremophore EL, tween 20 was selected as the 
surfactant and propylene glycol was selected as cosurfactant 
based on its emulsification properties and the resulting 
droplet size.
Fastest reconstitution and smallest particle size was 
achieved with formulation F2, in which the liquid SEDDS 
had a droplet size of 142.89nm and solid SEDDS had a 
droplet size of 160.47nm.
Conclusively, a SEDDS consisting of capmul MCM 
EP (40% v/v) emulsified with cremophore EL (40% 
v/v) and propylene glycol (20%v/v) was successfully 
developed with an increased dissolution rate, increased 
solubility and ultimately, increased permeability of a 
poorly water soluble drug, carvedilol. The liquid CAR 
SEDDS were converted into solid pellets by using 
the extrusion spheronization technique. The SEM 
characterization of SEDDS pellets revealed spherical 
shape of pellets. The developed formulation exhibited 
significantly higher dissolution property compared to 
6.25mg immediate release marketed tablet.
Thus, the SEDDS pellets could be an effective 
formulation strategy for other oil-soluble drugs with low 
oral absorption.
LIST OF ABBREVIATIONS
CAR-Carvedilol
SEDDS-Self emulsifying drug delivery system
SEM-Scanning electron microscopy
XRD-X ray diffraction
ES-Extrusion-spheronization
DSC-Differential scanning calorimetry
rpm-Revolutions per minute
nm- Nanometer
GIT- Gastro intestinal tract
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